Proposal would make aging research part of EU industrial policy, with trial funding and guaranteed purchases of successful drugs
Proposal would make aging research part of EU industrial policy, with trial funding and guaranteed purchases of successful drugs
Aging researcher Andrew Steele and lawyer Kamen Shoylev, co-founders of the think tank The Longevity Initiative, set out their proposals in a collection published by the European Liberal Forum political foundation on 9 November. They propose developing drugs that target shared processes of aging to delay several age-related diseases at once and extend life. The authors connect this goal to the freedom to choose how to live: “more healthy years mean more years of independence.”
Running a trial over several years to test an inexpensive drug for a new use is costly for a developer. If the patent has expired, competitors can also sell the drug once the trial succeeds. The company that paid for the trial then has a harder time recovering its investment.
Steele and Shoylev propose assessing how much funding the EU and individual countries already allocate to the biology of aging. Government and charitable grants should support research into aging mechanisms and potential interventions before a commercial product emerges. To train AI, the authors propose a shared European database of biological measurements linked to participants’ medical records. AI could use these data to identify patterns of aging and potential treatments. Data collection needs to begin well in advance: some changes become apparent only after years or decades of observation.
The authors propose reducing the cost of testing drugs by embedding trials in routine medical care. Such a study could compare two groups of patients: one receiving the study drug and the other receiving usual care. Diseases and side effects could be tracked through electronic medical records, reducing the costs of running the study.
They also propose validating measures of biological aging, including those derived from blood tests. Researchers would need to establish whether a drug-induced change in a measure is accompanied by delayed disease, preserved bodily function, or longer life. Following validation and recognition by the European Medicines Agency, a measure could accelerate trials in which the agency permits its use: treatment effects could be assessed sooner than changes in disease incidence and mortality. Many developers would be able to use a validated assessment method, so the authors propose sharing the cost of validation among governments, charities, or several companies.
Prizes for achieving specified outcomes and guaranteed purchases are intended to make successful trials financially worthwhile. A government would commit in advance to buying a treatment at an agreed price if it meets specified requirements. The authors intend these purchases to “reward the developer that conducts the trial,” regardless of patent status. A similar mechanism was used by Gavi, the Vaccine Alliance: donors pledged 1,5 billion dollars to support the market for vaccines against pneumococcus, a bacterium that causes pneumonia, while manufacturers committed to supplying them at an affordable price for ten years.
The authors propose recognizing aging as a treatment target in its own right within drug approval rules, allowing developers to seek approval for drugs specifically to treat aging.
- https://liberalforum.eu/publication/live-long-and-prosper/
- https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance/qualification-novel-methodologies-medicine-development-qonm
- https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-advance-market-commitment-amc/how-it-works